AbbVie’s Produodopa holds potential to become first-choice pump for advanced Parkinson’s 11-Jan-2024 By Isabel Cameron Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view: